Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Press Releases

16 Jul 2024

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogens for neuropsychiatric disorders, and Aries Science & Technology, a developer of encapsulation technologies, have announced a licensing agreement...

By Madison Roberts

Industry

15 Jul 2024

Integrating SoundSelf in Ketamine Clinics: Enhancing Patient Outcomes Through Immersive Technology

Ketamine clinics are revolutionizing mental health treatment for those with resistant depression and other conditions. Integrating SoundSelf, an immersive biofeedback and neurostimulation technology, can further enhance these therapies. This article...

By Madison Roberts

Industry

15 Jul 2024

Kathryn Walker: Six Years of Transformative Leadership in Mental Health Care at Revitalist

Kathryn A. Walker, a vanguard psychiatrist and anesthesia provider, and founder of Revitalist, is at the forefront of revolutionizing mental health care. Her latest innovation, Kate NeuroPsych, an AI bot...

By Madison Roberts

Industry

11 Jul 2024

Psychedelic Therapist Training: New Horizons and Opportunities in Psychedelic-Assisted Therapy

As the field of psychedelic therapy gains recognition and acceptance, a new avenue of opportunity is emerging for mental healthcare professionals. Over the past 70 years, psychedelic-assisted therapy has demonstrated...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

3 Jun 2024

The Emerging Landscape of Psychedelic Therapy: Education and Certification

The field of psychedelic therapy is experiencing a resurgence, highlighting the critical need for comprehensive training and certification programs. This article explores diverse training needs, ethical and regulatory considerations, and...

By Madison Roberts

Press Releases

30 May 2024

PurMinds NeuroPharma Announces PUR501 as Lead Candidate Novel Non-Hallucinogenic Neuroplastogen

PurMinds NeuroPharma to initiate preclinical development of lead candidate PUR501 in 2024 in preparation for IND submission....

By Madison Roberts

Culture

20 May 2024

Exploring the Psychedelic Frontier: Top Podcasts and Documentaries

From in-depth podcasts to compelling documentaries, there are numerous resources available for those interested in learning about these transformative experiences....

By Madison Roberts

Breaking News

14 May 2024

Advancing Mental Health Treatments: The Strategic Collaboration Between Enveric Biosciences and MindBio Therapeutics

In a groundbreaking move within the pharmaceutical industry, Enveric Biosciences (NASDAQ: ENVB) a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety,...

By Madison Roberts

Breaking News, Press Releases

13 May 2024

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

AbbVie and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research...

By Madison Roberts

Follow us on social

Latest News

You Might Also Like

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

WordPress Ads